Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

relatlimab 1pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cystoscopy 1Cisplatin 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Muscle Invasive Bladder Urothelial Carcinoma × Nivolumab × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡